Figure 1From: Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)Dose-limiting toxicity (DLT) events. Clinical events of toxicity related to MAPC infusions. If more than one DLT event occurs in a dose cohort, the study will be stopped.Back to article page